apdine syrup - Lomus Pharmaceuticals Pvt. Ltd.

APDINE Tablet/Syrup
Dosage Forms/Composition
Each uncoated tablet contains Cyproheptadine HCL mg.
Each 5ml of suspension contains cyproheptadine HCL equivalent to anhydrous
cyproheptadine HCL 2mg.
Pharmacological Index
Antihistamine
INDICATION
Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria.
Appetite enhancer
Pregnancy Risk Factor
B
Contraindications
Hypersensitivity to cyproheptadine or any component; narrow-angle glaucoma,
bladder neck obstruction, acute asthmatic attack, stenosing peptic ulcer, GI tract
obstruction, those on MAO inhibitors; avoid use in premature and term newborns due
to potential association with SIDS
Warnings/Precautions
Do not use in neonates, safety and efficacy have not been established in children 10%:
Central nervous system: Slight to moderate drowsiness
Respiratory: Thickening of bronchial secretions
1% to 10%:
Central nervous system: Headache, fatigue, nervousness, dizziness
Gastrointestinal: Appetite stimulation, nausea, diarrhea, abdominal pain, xerostomia
Neuromuscular & skeletal: Arthralgia
Respiratory: Pharyngitis

useful by reducing acetylcholinesterase. Anticholinesterase inhibitors include
physostigmine, neostigmine, pyridostigmine, and edrophonium. For anticholinergic
overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or 0.02
mg/kg for children) I.V., slowly may be given to reverse these effects.
Drug Interactions
Increased toxicity: MAO inhibitors hallucinations
Mechanism of Action
A potent antihistamine and serotonin antagonist, competes with histamine for H1-
receptor sites on effector cells in the gastrointestinal tract, blood vessels, and
respiratory tract
Pharmacodynamics/Kinetics
Metabolism: Almost completely
Elimination: >50% excreted in urine (primarily as metabolites); ~25% excreted in
feces
Usual Dosage
Oral:
2-6 years: 2 mg every 8-12 hours (not to exceed 12 mg/day)
7-14 years: 4 mg every 8-12 hours (not to exceed 16 mg/day)
Adults: 4-20 mg/day divided every 8 hours (not to exceed 0.5 mg/kg/day)
Dosing adjustment in hepatic impairment: Dosage should be reduced in patients with
significant hepatic dysfunction
Patient Information
Take as directed; do not exceed recommended dose. Avoid use of other depressants,
alcohol, or sleep-inducing medications unless approved by prescriber. You may
experience drowsiness or dizziness (use caution when driving or engaging in tasks
requiring alertness until response to drug is known); or dry mouth, nausea, or
abdominal pain (frequent small meals, frequent mouth care, chewing gum, or sucking
hard candy may help). Report persistent sedation, confusion, or agitation; changes in
urinary pattern; blurred vision; chest pain or palpitations; sore throat difficulty
breathing or expectorating (thick secretions); or lack of improvement or worsening or
condition. Breast-feeding precautions: Do not breast-feed.
LOMUS Drug Information Center
Lomus Pharmaceuticals Pvt. Ltd.
P.O. Box No 4506, Lomus House (Corporate office),
Kailash Chour, Lazimpat, Kathmandu, Nepal
Ph: 4436396 (Hunting Line). Fx: 977-1-4436395
E-mail: druginfo@lomus.com.np